Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
141 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Influenza A Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Influenza A Infections - Pipeline Review, H2 2014', provides an overview of the Influenza A Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Influenza A Infections Overview 8 Therapeutics Development 9 Pipeline Products for Influenza A Infections - Overview 9 Pipeline Products for Influenza A Infections - Comparative Analysis 10 Influenza A Infections - Therapeutics under Development by Companies 11 Influenza A Infections - Therapeutics under Investigation by Universities/Institutes 14 Influenza A Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Influenza A Infections - Products under Development by Companies 18 Influenza A Infections - Products under Investigation by Universities/Institutes 21 Influenza A Infections - Companies Involved in Therapeutics Development 22 Johnson & Johnson 22 Kyowa Hakko Kirin Co., Ltd. 23 Autoimmune Technologies, LLC 24 GlaxoSmithKline plc 25 Genentech, Inc. 26 Inovio Pharmaceuticals, Inc. 27 MedImmune, LLC 28 Crucell N.V. 29 Hemispherx Biopharma, Inc. 30 NanoViricides, Inc. 31 SIGA Technologies, Inc. (Inactive) 32 Vironova AB 33 CureVac GmbH 34 Chimerix, Inc. 35 Theraclone Sciences, Inc. 36 Immune Targeting Systems (ITS) Ltd. 37 Sinovac Biotech Ltd. 38 Microbiotix, Inc. 39 iBio, Inc. 40 Alios BioPharma, Inc. 41 Vivaldi Biosciences Inc. 42 Visterra, Inc. 43 ContraFect Corporation 44 Cure Lab, Inc. 45 Humabs BioMed SA 46 Microgen Scientific Industrial Company for Immunobiological Medicines 47 Influenza A Infections - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 FP-01 - Drug Profile 57 CR-8020 - Drug Profile 58 TCN-032 - Drug Profile 59 influenza vaccine (H5N2) - Drug Profile 61 RG-7745 - Drug Profile 62 diridavumab - Drug Profile 63 MEDI-550 - Drug Profile 65 influenza A vaccine (H7N7) - Drug Profile 67 VIS-410 - Drug Profile 68 Live Attenuated Vaccine for H5N2 Influenza - Drug Profile 69 GSK-3206641A - Drug Profile 70 GSK-3206640A - Drug Profile 71 Influenza A Vaccine [H7N9] - Drug Profile 72 GSK-3277510A - Drug Profile 73 GSK-3277509A - Drug Profile 74 Influenza Vaccine [H7N9] - Drug Profile 75 interferon alfa-n3 - Drug Profile 76 NVINF-2 - Drug Profile 78 Pandemic Influenza Vaccine (H1N1) - Drug Profile 79 Flufirvitide-3 - Drug Profile 80 NVINF-1 - Drug Profile 81 Nucleozin - Drug Profile 83 Small Molecule for Influenza A - Drug Profile 84 ET-001 - Drug Profile 85 CR-8043 - Drug Profile 86 FI-6 - Drug Profile 87 DNA Vaccine for H7N9 Universal Influenza - Drug Profile 88 Peptides for Influenza Infections - Drug Profile 89 Gamma-Flu - Drug Profile 90 Peptide to Agonize PAR-2 for Influenza A Infections - Drug Profile 91 VH-244 - Drug Profile 92 CF-401 - Drug Profile 94 CF-402 - Drug Profile 95 Panavimab A - Drug Profile 96 CLVax-1.0 - Drug Profile 97 Z-3G1 - Drug Profile 99 Small Molecules for Influenza A Infections - Drug Profile 100 Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A Virus Infections - Drug Profile 101 Small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile 102 Small Molecules to Block Influenza M2 Proton Channel for Influenza A Infections - Drug Profile 103 AL-18 - Drug Profile 104 influenza vaccine (H7N9) - Drug Profile 105 MBX-2329 - Drug Profile 106 MBX-2546 - Drug Profile 108 Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile 109 Small Molecule for Influenza Virus - Drug Profile 110 Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 111 VX-353 - Drug Profile 112 Small Molecules to Block M2 Proton Channel for Influenza A Infections - Drug Profile 113 Influenza A Infections - Recent Pipeline Updates 114 Influenza A Infections - Dormant Projects 125 Influenza A Infections - Discontinued Products 126 Influenza A Infections - Product Development Milestones 127 Featured News & Press Releases 127 Appendix 137 Methodology 137 Coverage 137 Secondary Research 137 Primary Research 137 Expert Panel Validation 137 Contact Us 138 Disclaimer 138
List of Tables Number of Products under Development for Influenza A Infections, H2 2014 12 Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Development by Companies, H2 2014 (Contd..1) 22 Products under Development by Companies, H2 2014 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2014 24 Influenza A Infections - Pipeline by Johnson & Johnson, H2 2014 25 Influenza A Infections - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 26 Influenza A Infections - Pipeline by Autoimmune Technologies, LLC, H2 2014 27 Influenza A Infections - Pipeline by GlaxoSmithKline plc, H2 2014 28 Influenza A Infections - Pipeline by Genentech, Inc., H2 2014 29 Influenza A Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 30 Influenza A Infections - Pipeline by MedImmune, LLC, H2 2014 31 Influenza A Infections - Pipeline by Crucell N.V., H2 2014 32 Influenza A Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2014 33 Influenza A Infections - Pipeline by NanoViricides, Inc., H2 2014 34 Influenza A Infections - Pipeline by SIGA Technologies, Inc. (Inactive), H2 2014 35 Influenza A Infections - Pipeline by Vironova AB, H2 2014 36 Influenza A Infections - Pipeline by CureVac GmbH, H2 2014 37 Influenza A Infections - Pipeline by Chimerix, Inc., H2 2014 38 Influenza A Infections - Pipeline by Theraclone Sciences, Inc., H2 2014 39 Influenza A Infections - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014 40 Influenza A Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 41 Influenza A Infections - Pipeline by Microbiotix, Inc., H2 2014 42 Influenza A Infections - Pipeline by iBio, Inc., H2 2014 43 Influenza A Infections - Pipeline by Alios BioPharma, Inc., H2 2014 44 Influenza A Infections - Pipeline by Vivaldi Biosciences Inc., H2 2014 45 Influenza A Infections - Pipeline by Visterra, Inc., H2 2014 46 Influenza A Infections - Pipeline by ContraFect Corporation, H2 2014 47 Influenza A Infections - Pipeline by Cure Lab, Inc., H2 2014 48 Influenza A Infections - Pipeline by Humabs BioMed SA, H2 2014 49 Influenza A Infections - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014 50 Assessment by Monotherapy Products, H2 2014 51 Number of Products by Stage and Target, H2 2014 53 Number of Products by Stage and Mechanism of Action, H2 2014 55 Number of Products by Stage and Route of Administration, H2 2014 57 Number of Products by Stage and Molecule Type, H2 2014 59 Influenza A Infections Therapeutics - Recent Pipeline Updates, H2 2014 117 Influenza A Infections - Dormant Projects, H2 2014 128 Influenza A Infections - Discontinued Products, H2 2014 129
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
